222 related articles for article (PubMed ID: 28704186)
21. [Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma].
Wang K; Gong H; Li X; Yang Z; Cao P; Wand C; Jiang Y; Wang H; Wang Y; Zhang G
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):170-4. PubMed ID: 26268750
[TBL] [Abstract][Full Text] [Related]
22. The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.
Ma Y; Fan M; Dai L; Kang X; Liu Y; Sun Y; Yan W; Liang Z; Xiong H; Chen K
Tumour Biol; 2015 Sep; 36(10):8085-92. PubMed ID: 25982999
[TBL] [Abstract][Full Text] [Related]
23. Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma.
Wakejima R; Inamura K; Ninomiya H; Nagano H; Mun M; Okumura S; Okubo K; Ishikawa Y
Pathol Int; 2020 Feb; 70(2):72-83. PubMed ID: 31859434
[TBL] [Abstract][Full Text] [Related]
24. Ribonucleic Acid In Situ Hybridization Is a More Sensitive Method Than Immunohistochemistry in Detection of Thyroid Transcription Factor 1 and Napsin A Expression in Lung Adenocarcinomas.
Shi J; Liu H; Ma XJ; Chen Z; He MX; Luo Y; Lin F
Arch Pathol Lab Med; 2016 Apr; 140(4):332-40. PubMed ID: 27028392
[TBL] [Abstract][Full Text] [Related]
25. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
Mukhopadhyay S; Katzenstein AL
Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
[TBL] [Abstract][Full Text] [Related]
26. Utility of TTF-1 and Napsin-A in the work-up of malignant effusions.
El Hag M; Schmidt L; Roh M; Michael CW
Diagn Cytopathol; 2016 Apr; 44(4):299-304. PubMed ID: 26799356
[TBL] [Abstract][Full Text] [Related]
27. [Lung non-terminal respiratory unit type adenocarcinoma: a clinicopathologic study].
Liu B; Wu N; Shen Q; Shi SS; Zhang SS; Ru Y; Rao Q; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):603-608. PubMed ID: 30107665
[No Abstract] [Full Text] [Related]
28. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung.
Ye J; Findeis-Hosey JJ; Yang Q; McMahon LA; Yao JL; Li F; Xu H
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):313-7. PubMed ID: 21464700
[TBL] [Abstract][Full Text] [Related]
29. Mucinous micropapillary pattern in lung adenocarcinomas: a unique histology with genetic correlates.
Kamata T; Yoshida A; Shiraishi K; Furuta K; Kosuge T; Watanabe S; Asamura H; Tsuta K
Histopathology; 2016 Feb; 68(3):356-66. PubMed ID: 26109197
[TBL] [Abstract][Full Text] [Related]
30. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
[TBL] [Abstract][Full Text] [Related]
31. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component.
Xu Y; Zheng M; Wang N; Wang R
Med Sci Monit; 2019 Nov; 25():8492-8498. PubMed ID: 31710020
[TBL] [Abstract][Full Text] [Related]
33. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
34. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
35. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
Bishop JA; Sharma R; Illei PB
Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis and comparison of napsin A, TTF1, SPA and CK7 expression in primary lung adenocarcinoma.
Jin L; Liu Y; Wang X; Qi X
Biotech Histochem; 2018; 93(5):364-372. PubMed ID: 29956575
[TBL] [Abstract][Full Text] [Related]
37. Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive?
Usuda K; Sagawa M; Motono N; Ueno M; Tanaka M; Machida Y; Matoba M; Taniguchi M; Tonami H; Ueda Y; Sakuma T
Asian Pac J Cancer Prev; 2014; 15(2):657-62. PubMed ID: 24568474
[TBL] [Abstract][Full Text] [Related]
38. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
39. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
Finberg KE; Sequist LV; Joshi VA; Muzikansky A; Miller JM; Han M; Beheshti J; Chirieac LR; Mark EJ; Iafrate AJ
J Mol Diagn; 2007 Jul; 9(3):320-6. PubMed ID: 17591931
[TBL] [Abstract][Full Text] [Related]
40. HNF4α as a marker for invasive mucinous adenocarcinoma of the lung.
Sugano M; Nagasaka T; Sasaki E; Murakami Y; Hosoda W; Hida T; Mitsudomi T; Yatabe Y
Am J Surg Pathol; 2013 Feb; 37(2):211-8. PubMed ID: 23108025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
